Patients and Methods
CAPRISTANA was an international, observational cohort study examining cabazitaxel use for the treatment of patients with mCRPC. Effectiveness was assessed by overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF) and disease control rate. HRQoL was assessed using the Functional Assessment of Cancer Therapy-Prostate questionnaire (FACT-P) and the three-level European Quality of Life questionnaire (EQ-5D-3L). Safety was assessed by adverse event (AE) reporting.
Results
A total of 189 patients were treated across 54 centres between April 2012 and June 2016. At baseline, 58.7% had ≥1 comorbidity, 93.7% had an Eastern Cooperative Oncology Group performance status ≤1, and 60.1% had a Gleason score at diagnosis of ≥8. Patients received a median of 6 cabazitaxel cycles; 84.7% received cabazitaxel as second-line therapy. The median OS, PFS and TTF were 13.2, 5.6 and 4.4 months, respectively. Cabazitaxel led to disease control in 52.9% of patients. HRQoL was maintained (40.3%) or improved (32.2%) in 72.5% of patients based on total FACT-P scores. Interestingly, 53.6% of patients reported pain improvement and a further 21.2% maintained pain control based on FACT-P prostate cancer-specific pain scores. The most common treatment-related grade ≥3 AEs were neutropenia (7.9%) and anaemia (2.1%).
Introduction
Prostate cancer is the second most frequently diagnosed cancer type in men [1] . Although early diagnosis is associated with better prognosis, patients with metastatic castrationresistant prostate cancer (mCRPC) typically have poorer outcomes [2] . Several new treatments have been developed in the last 7 years including docetaxel, cabazitaxel, abiraterone acetate, enzalutamide, sipuleucel-T and radium-223 [3] [4] [5] [6] [7] [8] [9] . Cabazitaxel was approved in 2010 as a second-line chemotherapy in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen based on the phase III TROPIC study [6, 9, 10] . Cabazitaxel is a next-generation taxane, selected for testing in clinical trials based on activity in docetaxel-sensitive and -resistant cell lines [11] . Cabazitaxel also exhibits stronger suppression of microtubule dynamics, faster cellular uptake and better intracellular retention than docetaxel in vitro [12] .
Because of the exclusive design of clinical trials, patients with additional complicating factors, such as comorbidities and advanced age, are frequently not included. Real-world studies provide an opportunity to validate the outcomes reported in large phase III trials using diverse patient populations and to identify unmet medical needs to better guide research and improve patient care. These studies help identify potential treatment risk factors, trends in healthcare service utilization, disparities in treatment access and healthrelated quality of life (HRQoL), and costs associated with disease management [13] .
The TROPIC and PROSELICA randomized clinical trials demonstrated the efficacy and safety of cabazitaxel; however, the effectiveness of cabazitaxel and its impact on HRQoL in routine clinical practice is still unknown.
CAPRISTANA, an international, multicentre, observational, prospective cohort study examined the use of cabazitaxel in conjunction with prednisone or prednisolone in routine clinical practice settings in patients with mCRPC. The primary objective was to observe the usage patterns of cabazitaxel; secondary objectives included further description of cabazitaxel usage patterns (subsequent therapies and use of granulocyte-colony stimulating factor [G-CSF] 
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Study Design and Population
CAPRISTANA was a non-interventional registry study (CABAZC 06092). Patients with mCRPC were enrolled across 54 centres in Lebanon, Czech Republic, Spain, Austria, Russia and Bulgaria. To be included in the study patients had to have a diagnosis of mCRPC, be aged ≥18 years, have received previous treatment with docetaxel and be scheduled to receive cabazitaxel as prescribed by their physician. Exclusion criteria included previous treatment with cabazitaxel or participation in another clinical study at the time of enrolment. All patients provided written consent prior to enrolment in the study, which was reviewed and approved by the appropriate Ethics Committee.
Data were recorded using an electronic case report form for ≤1.5 years after the first cabazitaxel dose or until death, whichever occurred first. The same electronic case report form was used across centres to gather information about patient and disease characteristics. Data were recorded at baseline, and every 3 months (AE15 days) for endpoint analysis. Baseline data included: patient characteristics ( 
Use of Cabazitaxel
Patients with mCRPC scheduled to receive cabazitaxel were prescribed the recommended dose at the time of 25 mg/m 2 , administered as a 1-h intravenous infusion every 3 weeks in combination with oral prednisone or prednisolone 10 mg daily. Some patients received a starting dose of 20 mg/m 2 as directed by their physician. Patients were allowed G-CSF from cycle 1.
Efficacy Assessments
Overall survival was evaluated from date of first cabazitaxel administration to date of death from any cause. PFS was evaluated from the date of first cabazitaxel administration to the date of disease progression or death from any cause. Disease progression was defined as tumour or clinical progression or rising PSA level during or after cabazitaxel therapy. TTF was evaluated from the date of first administration of cabazitaxel to the date of cabazitaxel discontinuation, regardless of the cause. Criteria for response rate included PSA, clinical symptoms (including pain) and tumour imaging. Patients were assessed for efficacy at week 12, as recommended by Prostate Cancer Clinical Trials Working Group 2 guidelines.
Health-related Quality of Life Assessments
Health-related quality of life was assessed based on the results of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) and the three-level European Quality of Life (EQ-5D-3L) questionnaires provided at baseline and every two cycles until cabazitaxel discontinuation, then every 3 months until death or 1.5 years after treatment discontinuation.
The FACT-P is a validated multidimensional prostate cancerspecific patient-reported outcome measure [14] . The questionnaire consists of five subscales: physical, social, emotional and functional well-being, and a prostate cancer-subscale (PCS). The five subscales are summed to derive the FACT-P total score, which ranges from a minimum of 0 to a maximum of 156, with higher values representing better HRQoL [15, 16] . PCS-pain is a pain-related score ranging from 0 to 16 based on four questions from the FACT-P questionnaire interrogating pain specifically (P1, P2, P3, GP4) [14] . Differences in scores were clinically important if there was a change of AE10 points for the FACT-P total score, AE3 points for the FACT-P subscales (physical, social, emotional and functional well-being, and PCS) and AE2 points for the FACT-P PCS-pain score [14] .
The EQ-5D-3L is a widely used generic patient-reported outcome instrument in clinical trials and observational studies [17, 18] . The questionnaire assesses three levels of impairment in five dimensions of health: mobility; self-care; usual activities; pain/discomfort; and anxiety/depression, and includes a visual analogue scale (VAS) [17, 18] . EQ-5D-3L scores are converted into health state utility values using the UK 3L valuation set (with health state utility value scores ranging from À0.594 to 1.0). The EQ-5D-VAS 'thermometer' scores range from 0 to 100, with higher values representing a better health state [17, 18] . Differences in score were clinically important if there was a change of AE7 points on the EQ-5D VAS and AE0.074 points for the EQ-5D health state utility value score [19, 20] .
Safety Assessments
Adverse events (AEs) were collected from the time the patients signed the informed consent form to 30 days after the last administration of cabazitaxel. Treatment-emergent adverse events (TEAEs) were defined as AEs that began, worsened or became serious between the first administration of cabazitaxel and 30 days after the last administration of cabazitaxel during the study. Serious AEs occurring >30 days after last treatment with cabazitaxel that were considered to be related to cabazitaxel treatment were also collected.
Statistical Considerations
The analyses of this study were descriptive, and the sample size was calculated based on 95% CIs associated with event rate estimations for individual countries to obtain sufficient data to fulfil post-reimbursement requirements. All summaries and statistical analyses were generated using SAS software version 9.2. Time-to-event outcomes were computed using the Kaplan-Meier estimates (95% CI), and the median survival times (with 95% CI) were provided.
Results
Patient Characteristics
A total of 191 patients were enrolled in the CAPRISTANA study, of whom 189 received cabazitaxel between April 2012 and June 2016. Patients had a median age of 69 years (Table 1) . Most patients had an ECOG-PS ≤1 (177 patients; 93.7%), a Gleason score at diagnosis of ≥8 (107 patients; 60.1%) and ≥1 comorbidity at baseline (111 patients; 58.7%). Most patients had bone metastases (165 patients; 87.3%). The median time from prostate cancer diagnosis to enrolment was 4.0 years, and 17.0 months from diagnosis of mCRPC to enrolment. All patients received at least one cycle of docetaxel before beginning treatment with cabazitaxel. Patients received a median of 6 docetaxel cycles prior to cabazitaxel, with 114 (60.3%) discontinuing docetaxel in the previous line because of disease progression. Patients also received nonchemotherapy-based treatments including 72 (38.1%) who received prostate cancer surgery, 100 (52.9%) who underwent radiotherapy and 178 (94.2%) who received some form of hormonal therapy.
Clinical Use of Cabazitaxel
For the 189 patients who were treated with cabazitaxel, 160 (84.7%) received cabazitaxel as second-line chemotherapy ( Table 2 ). Patients received a median (range) of 6 (1-24) cabazitaxel cycles. G-CSF was received by 107 patients (56.6%) during cycle 1, with 100 patients (52.9%) receiving prophylactic G-CSF and seven (3.7%) receiving therapeutic G-CSF.
All patients discontinued cabazitaxel, with 111 (58.7%) discontinuing as a result of disease progression, 28 (14.8%) at patient request, and 28 (14.8%) for 'other' reasons, i.e. physician's direction, end of scheduled treatment or end of the 1.5-year follow-up period (Table 2) . AEs were the least common reason for patients to discontinue cabazitaxel (22 patients; 11.6%). Dose modifications were required in 103 patients (54.5%), with dose delay being required in 96 of these patients. Non-AE-related events were the most frequent (42.9%) reasons for dose delay. Dose reduction was required in 27 patients (14.3%). After discontinuing cabazitaxel, 74 patients (39.2%) received hormonal therapy and 28 (14.8%) received chemotherapy.
Efficacy
The median OS was 13.2 months, median PFS was 5.6 months and median TTF was 4.4 months (Fig. 1) . Cabazitaxel led to disease control in 52.9% of patients; of these, 1.1% achieved complete response, 22.2% achieved partial response and 29.6% achieved stable disease. Progressive disease was reported in 39.7% of patients. Efficacy was not evaluable in 14 patients (7.4%).
Health-related Quality of Life
Of 189 patients, 158 (84%) completed HRQoL questionnaires. During the course of the study, HRQoL remained stable (40.3%) or improved (32.2%) in 72.5% of patients based on FACT-P total score, and pain improved for over half of patients (53.6%) based on the PCS-pain score (Table 3 ). There were no clinically relevant declines (≥10) in mean change in FACT-P total and (≥3) subscale scores (Fig. 2) ; however, there was a clinically meaningful decline after cycle 10 for the <10 patients who remained on treatment (data not shown). There was a trend towards a clinically important improvement in FACT-P PCS score (≥3) at cycle 3 and for FACT-P PCS-pain score (≥2) at cycle 8.
Maintenance and improvement of HRQoL was also supported by the EQ-5D-VAS scores, which did not show clinically relevant changes (AE7) from baseline during the course of treatment until cycles 6, 8 and 10, at which point clinically important improvements were seen (Fig. 3) .
Safety
Treatment-emergent adverse events of any grade possibly related to cabazitaxel were reported in 37.6% of patients, and 13.8% of patients experienced TEAEs of grade ≥3 (Table 4) . The most common clinical TEAEs of any grade possibly related to cabazitaxel were anaemia (10.6%), neutropenia (9.5%), diarrhoea (8.5%) and asthenia (7.9%). Clinical neutropenia and anaemia were the most common grade ≥3 TEAEs (7.9% and 2.1%, respectively). Serious TEAEs possibly related to cabazitaxel were reported in 12.2% of patients, the most common of which was neutropenia (5.8%). ECOG PS, Eastern Cooperative Oncology Group performance status; FACT-P, Functional Assessment of Cancer Therapy-Prostate; HRQoL, health-related quality of life; mCRPC, metastatic castration-resistant prostate cancer; PCS, prostate cancer subscale; Q1-Q3, quartiles. *Higher values represent better HRQoL. The FACT-P score scale ranged from 0 to 28 for physical, social and functional well-being, 0-24 for social well-being, 0-48 for prostate cancer subscale, 0-16 for prostate cancer subscalepain, and 0-156 for FACT-P total score. † n = 157. ‡ n = 155. § n = 156. 
Discussion
The CAPRISTANA study was a multinational, prospective, non-interventional study designed to observe the use of cabazitaxel and evaluate real-world effectiveness, HRQoL and safety. Patients enrolled in the CAPRISTANA study were similar to those enrolled in the pivotal phase III trials of cabazitaxel (TROPIC and PROSELICA). The proportion of patients with an ECOG-PS ≤1 was similar across all three studies (CAPRISTANA: 93.7%, TROPIC: 91.9%, PROSELICA: 89.7%). The presence of bone metastases was also similar (CAPRISTANA: 87.3%, TROPIC: 83.6%, PROSELICA: 94.5%). Although patients' median age in CAPRISTANA was similar to that in TROPIC, there were more patients aged ≥75 years in CAPRISTANA (23.8%) than TROPIC (18.4%) [9, 21, 22] . The median number of treatment cycles administered, as well as discontinuation rates and rationales, TEAEs, rate and type of serious TEAEs (especially concerning grade ≥3 neutropenia and anaemia) were similar between CAPRISTANA and the previous clinical trials [9, 21] .
Most patients in CAPRISTANA received cabazitaxel as a second-line therapy as per the labelling instructions; however, 15% of patients were prescribed cabazitaxel in third or later Table 3 Health-related quality of life responder analysis by FACT-P questionnaire subscales and summary score. lines of therapy. Most patients discontinued cabazitaxel because of disease progression (58.7%); only 11.6% discontinued because of AEs. This contrasts with the TROPIC trial, where 47.6% discontinued treatment because of disease progression and 17.7% as a result of AEs [9] . In CAPRISTANA, patients more often received hormonal therapies (39.2%) after cabazitaxel treatment than chemotherapy rechallenge (14.8%). Investigation into patient outcomes after these additional therapies is warranted because optimal treatment sequences are still unknown.
Patients enrolled in CAPRISTANA had similar clinical response rates to cabazitaxel as those included in TROPIC and PROSELICA [9, 19] . The median OS was 13.2 months in CAPRISTANA, which was similar to that reported in TROPIC (15.1 months) and in PROSELICA (14.5 months) [9, 19] . In CAPRISTANA, the best overall response was complete response in 1.1% and partial response in 22.2% of patients; in PROSELICA, 0.4% and 23.0% had complete response and partial response, respectively. Because of differences in how progression was measured, this result cannot be compared with TROPIC or PROSELICA.
The HRQoL improvements were maintained or improved in 72.5% of patients based on the FACT-P total score and pain improved in over half of patients based on the FACT-P PCSpain score, with most patients reporting improvements within the first 10 cycles of treatment. In TROPIC, 9.2% of patients had a pain response associated with cabazitaxel, compared with 7.7% of patients who received mitoxantrone, although this was not significantly different (P = 0.63), as assessed by the Present Pain Intensity score on the McGill-Melzack scale [19, 23] . The Present Pain Intensity score was also used in a Swiss registry study observing patients in the routine clinical practice setting [24] . In CAPRISTANA, 53.6% reported pain improvement and a further 21.2% maintained pain control, as determined by FACT-P PCS-pain score. To our knowledge, this is the first report of maintained or improved pain control based on FACT-P PCS-pain score for cabazitaxel treatment in patients with mCRPC in routine clinical practice.
No new safety concerns were identified; patient toxicity profiles were similar to previous reports. Previously, the published incidence of grade ≥3 neutropenia in prospective [19, 20] . Positive changes indicate improvement in health-related quality of life, negative changes indicate deterioration. *Decline in EQ-5D-VAS score from baseline for cycle 7 may be a result of a low number of patients providing feedback. phase III trials was based on laboratory assessments, and was 82% in TROPIC and 73.3% in PROSELICA [9, 19] . Similarly, the rates of laboratory grade ≥3 anaemia were 11% and 14% in TROPIC and PROSELICA, respectively. In CAPRISTANA, neutropenia and anaemia rates were only recorded based on symptomatic, clinical AEs (as opposed to laboratory assessments), incidences of which were similar to those recorded in the clinical trials. The rates of possibly related grade ≥3 clinical neutropenia were 7.9% in CAPRISTANA, 21.3% in TROPIC and 9.6% in PROSELICA. Similarly, the rates of possibly related grade ≥3 clinical anaemia were 2.1% in CAPRISTANA, 2.7% in TROPIC and 2.4% in PROSELICA (Sanofi; data on file). G-CSF use was permitted in PROSELICA, but avoided during the first cycle, and no restrictions were applied in CAPRISTANA. The question of whether early prophylactic use of G-CSF may help reduce neutropenia rates associated with cabazitaxel administration merits further study.
Limitations of the present study include variability among the sites regarding use of electronic record forms, which could potentially lead to missing data and incomplete representation of cabazitaxel use in the clinical setting. There were also 14 patients who were not evaluable for efficacy. Additionally, only nine patients received >10 cycles of cabazitaxel; consequently, results after cycle 10 must be interpreted with caution.
In summary, cabazitaxel was predominately used as a secondline chemotherapy, with patients receiving a median of 6 cycles. Patients enrolled in CAPRISTANA had similar disease outcomes compared with patients in TROPIC and PROSECLICA, which supports the effectiveness and safety of cabazitaxel for patients with mCRPC. Results of the study also show maintenance or improvement in HRQoL in the majority of patients and reduction of pain in over half of patients. These real-world data help to better understand the effectiveness of cabazitaxel and its impact on mCRPC-related HRQoL and pain in a routine clinical setting.
